These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3500719)

  • 21. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.
    Halliday RC; Jones BC; Smith DA; Kitteringham NR; Park BK
    Br J Clin Pharmacol; 1995 Oct; 40(4):369-78. PubMed ID: 8554939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Competition between cytochrome P-450 isozymes for NADPH-cytochrome P-450 oxidoreductase affects drug metabolism.
    Li DN; Pritchard MP; Hanlon SP; Burchell B; Wolf CR; Friedberg T
    J Pharmacol Exp Ther; 1999 May; 289(2):661-7. PubMed ID: 10215637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of propranolol and irreversible binding to rat liver microsomes: strain differences and effects of inhibitors.
    Masubuchi Y; Narimatsu S; Suzuki T
    Biochem Pharmacol; 1992 Feb; 43(3):635-7. PubMed ID: 1540217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
    Gut J; Gasser R; Dayer P; Kronbach T; Catin T; Meyer UA
    FEBS Lett; 1984 Aug; 173(2):287-90. PubMed ID: 6146537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man.
    Kobayashi S; Murray S; Watson D; Sesardic D; Davies DS; Boobis AR
    Biochem Pharmacol; 1989 Sep; 38(17):2795-9. PubMed ID: 2775304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling.
    Wolff T; Distlerath LM; Worthington MT; Groopman JD; Hammons GJ; Kadlubar FF; Prough RA; Martin MV; Guengerich FP
    Cancer Res; 1985 May; 45(5):2116-22. PubMed ID: 3921236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
    Masubuchi Y; Hosokawa S; Horie T; Suzuki T; Ohmori S; Kitada M; Narimatsu S
    Drug Metab Dispos; 1994; 22(6):909-15. PubMed ID: 7895609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impairment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranolol.
    Masubuchi Y; Fujita S; Chiba M; Kagimoto N; Umeda S; Suzuki T
    Biochem Pharmacol; 1991 Mar 15-Apr 1; 41(6-7):861-5. PubMed ID: 2009081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
    McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
    Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
    Boobis AR; Murray S; Kahn GC; Robertz GM; Davies DS
    Mol Pharmacol; 1983 Mar; 23(2):474-81. PubMed ID: 6220203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Basic characteristics of rat brain microsomal estradiol 2-hydroxylase].
    Tsukamoto T
    Nihon Naibunpi Gakkai Zasshi; 1990 Mar; 66(3):159-67. PubMed ID: 2347419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase.
    Modi S; Gilham DE; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
    Biochemistry; 1997 Apr; 36(15):4461-70. PubMed ID: 9109653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.
    Distlerath LM; Guengerich FP
    Proc Natl Acad Sci U S A; 1984 Dec; 81(23):7348-52. PubMed ID: 6594694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes.
    Relling MV; Evans WE; Fonné-Pfister R; Meyer UA
    Cancer Res; 1989 Jan; 49(1):68-71. PubMed ID: 2908853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
    Mankowski DC
    Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism.
    Gonzalez FJ; Matsunaga T; Nagata K; Meyer UA; Nebert DW; Pastewka J; Kozak CA; Gillette J; Gelboin HV; Hardwick JP
    DNA; 1987 Apr; 6(2):149-61. PubMed ID: 3582092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the cytochrome P450 isozyme that metabolizes ochratoxin A, using metabolic inducers, inhibitors and antibodies.
    Hietanen E; Bartsch H; Béréziat JC; Castegnaro M; Michelon J
    IARC Sci Publ; 1991; (115):297-304. PubMed ID: 1820345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of N-oxygenation to the metabolism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by various liver preparations.
    Cashman JR; Ziegler DM
    Mol Pharmacol; 1986 Feb; 29(2):163-7. PubMed ID: 3485239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.